Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More

18 May 2023

• By Pink Sheet Team

Short stories about how US FDA’s conference center changed since COVID-19 forced the end of in-person public events, what the agency did to officially close the books on Makena, and more.

GDUFA regulatory science priorities meeting — The FY 2023 generic drug regulatory science priorities meeting at the US FDA seemed familiar. • Source: Derrick Gingery

Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More

More from US FDA

More from Agency Leadership